HSD3B1 and resistance to androgen-deprivation therapy in prostate cancer: a retrospective, multicohort study

The Lancet Oncology

Volumn 17, Issue 10, 2016, Pages 1435-1444

  Hearn, Jason W D ^a,d   AbuAli, Ghada ^b   Reichard, Chad A ^b   Reddy, Chandana A ^a   Magi Galluzzi, Cristina ^c   Chang, Kai Hsiung ^b   Carlson, Rachel ^e   Rangel, Laureano ^e   Reagan, Kevin ^e   Davis, Brian J ^e   Karnes, R Jeffrey ^e   Kohli, Manish ^e   Tindall, Donald ^e   Klein, Eric A ^b   Sharifi, Nima ^a,b  

^a TAUSSIG CANCER INSTITUTE   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

^c Pathology and Laboratory Medicine Institute   (United States)

^d UNIVERSITY OF MICHIGAN   (United States)

^e MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROSTANOLONE; 3 BETA-HYDROXYSTEROID OXIDOREDUCTASE-DELTA(5) 3-KETOSTEROID ISOMERASE; 3BETA HYDROXY DELTA5 STEROID DEHYDROGENASE; ANTIANDROGEN; MULTIENZYME COMPLEX; STEROID DELTA ISOMERASE;

ADULT; AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; CANCER RESISTANCE; COHORT ANALYSIS; CONTROLLED STUDY; DISTANT METASTASIS FREE SURVIVAL; GENE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HETEROZYGOTE; HOMOZYGOTE; HSD3B1 GENE; HUMAN; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; POSTOPERATIVE PERIOD; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; PROSTATE CANCER; PROSTATECTOMY; RETROSPECTIVE STUDY; GENETICS; MIDDLE AGED; MORTALITY; PROSTATIC NEOPLASMS; SINGLE NUCLEOTIDE POLYMORPHISM;

AGED; ANDROGEN ANTAGONISTS; COHORT STUDIES; GENOTYPE; HUMANS; MALE; MIDDLE AGED; MULTIENZYME COMPLEXES; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGESTERONE REDUCTASE; PROSTATECTOMY; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; STEROID ISOMERASES;

EID: 84992390149     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(16)30227-3     Document Type: Article

References (42)

1. 1 Huggins, C, Hodges, CV, Studies on prostatic cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1 (1941), 293–297.
2. 2 Bolla, M, Gonzalez, D, Warde, P, et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med 337 (1997), 295–300.
3. 3 D'Amico, AV, Chen, MH, Renshaw, AA, Loffredo, M, Kantoff, PW, Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial. JAMA 299 (2008), 289–295.
4. 4 Messing, EM, Manola, J, Sarosdy, M, Wilding, G, Crawford, ED, Trump, D, Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med 341 (1999), 1781–1788.
5. 5 Hussain, M, Tangen, CM, Berry, DL, et al. Intermittent versus continuous androgen deprivation in prostate cancer. N Engl J Med 368 (2013), 1314–1325.
6. 6 Moul, JW, Wu, H, Sun, L, et al. Early versus delayed hormonal therapy for prostate specific antigen only recurrence of prostate cancer after radical prostatectomy. J Urol 171 (2004), 1141–1147.
7. 7 Duchesne, GM, Woo, HH, Bassett, JK, et al. Timing of androgen-deprivation therapy in patients with prostate cancer with a rising PSA (TROG 03.06 and VCOG PR 01–03 [TOAD]): a randomised, multicentre, non-blinded, phase 3 trial. Lancet Oncol 17 (2016), 727–737.
8. 8 Crawford, ED, Eisenberger, MA, McLeod, DG, et al. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med 321 (1989), 419–424.
9. 9 Eisenberger, MA, Blumenstein, BA, Crawford, ED, et al. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N Engl J Med 339 (1998), 1036–1042.
10. 10 Scher, HI, Sawyers, CL, Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. J Clin Oncol 23 (2005), 8253–8261.
11. 11 Antonarakis, ES, Lu, C, Wang, H, et al. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med 371 (2014), 1028–1038.
12. 12 Mohler, JL, Gregory, CW, Ford, OH 3rd, et al. The androgen axis in recurrent prostate cancer. Clin Cancer Res 10 (2004), 440–448.
13. 13 Montgomery, RB, Mostaghel, EA, Vessella, R, et al. Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res 68 (2008), 4447–4454.
14. 14 de Bono, JS, Logothetis, CJ, Molina, A, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 364 (2011), 1995–2005.
15. 15 Ryan, CJ, Smith, MR, de Bono, JS, et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 368 (2013), 138–148.
16. 16 Scher, HI, Fizazi, K, Saad, F, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 367 (2012), 1187–1197.
17. 17 Beer, TM, Armstrong, AJ, Rathkopf, DE, et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med 371 (2014), 424–433.
18. 18 Ryan, CJ, Smith, MR, Fizazi, K, et al. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 16 (2015), 152–160.
19. 19 Stanbrough, M, Bubley, GJ, Ross, K, et al. Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res 66 (2006), 2815–2825.
20. 20 Chang, KH, Li, R, Kuri, B, et al. A gain-of-function mutation in DHT synthesis in castration-resistant prostate cancer. Cell 154 (2013), 1074–1084.
21. 21 Simard, J, Ricketts, ML, Gingras, S, Soucy, P, Feltus, FA, Melner, MH, Molecular biology of the 3β-hydroxysteroid dehydrogenase/Δ5-Δ4 isomerase gene family. Endocr Rev 26 (2005), 525–582.
22. 22 NCBI dbSNP database. dbSNP short genetic variations. http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=1047303 (accessed Jan 9, 2016).
23. 23 Wu, G, Huang, S, Nastiuk, KL, et al. Variant allele of HSD3B1 increases progression to castration-resistant prostate cancer. Prostate 75 (2015), 777–782.
24. 24 Stephenson, AJ, Kattan, MW, Eastham, JA, et al. Defining biochemical recurrence of prostate cancer after radical prostatectomy: a proposal for a standardized definition. J Clin Oncol 24 (2006), 3973–3978.
25. 25 Baak-Pablo, R, Dezentje, V, Guchelaar, HJ, van der Straaten, T, Genotyping of DNA samples isolated from formalin-fixed paraffin-embedded tissues using preamplification. J Mol Diagn 12 (2010), 746–749.
26. 26 Lehmann, U, Kreipe, H, Real-time PCR analysis of DNA and RNA extracted from formalin-fixed and paraffin-embedded biopsies. Methods 25 (2001), 409–418.
27. 27 Okello, JB, Zurek, J, Devault, AM, et al. Comparison of methods in the recovery of nucleic acids from archival formalin-fixed paraffin-embedded autopsy tissues. Anal Biochem 400 (2010), 110–117.
28. 28 Greene, FL, Page, DL, Flemind, ID, et al. American Joint Committee on Cancer. AJCC cancer staging manual, 6th edn., 2002, Springer, New York, xiv 421.
29. 29 Levesque, E, Huang, SP, Audet-Walsh, E, et al. Molecular markers in key steroidogenic pathways, circulating steroid levels, and prostate cancer progression. Clin Cancer Res 19 (2013), 699–709.
30. 30 van den Boom, D, Wjst, M, Everts, RE, MALDI-TOF mass spectrometry. Methods Mol Biol 1015 (2013), 71–85.
31. 31 Syrmis, MW, Moser, RJ, Whiley, DM, et al. Comparison of a multiplexed MassARRAY system with real-time allele-specific PCR technology for genotyping of methicillin-resistant Staphylococcus aureus. Clin Microbiol Infect 17 (2011), 1804–1810.
32. 32 Ross, RW, Oh, WK, Xie, W, et al. Inherited variation in the androgen pathway is associated with the efficacy of androgen-deprivation therapy in men with prostate cancer. J Clin Oncol 26 (2008), 842–847.
33. 33 Yang, M, Xie, W, Mostaghel, E, et al. SLCO2B1 and SLCO1B3 may determine time to progression for patients receiving androgen deprivation therapy for prostate cancer. J Clin Oncol 29 (2011), 2565–2573.
34. 34 Wright, JL, Kwon, EM, Ostrander, EA, et al. Expression of SLCO transport genes in castration-resistant prostate cancer and impact of genetic variation in SLCO1B3 and SLCO2B1 on prostate cancer outcomes. Cancer Epidemiol Biomarkers Prev 20 (2011), 619–627.
35. 35 Wang, X, Harshman, LC, Xie, W, et al. Association of SLCO2B1 genotypes with time to progression and overall survival in patients receiving androgen-deprivation therapy for prostate cancer. J Clin Oncol 34 (2016), 352–359.
36. 36 Prostate Cancer Trialists Collaborative Group. Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Prostate Cancer Trialists' Collaborative Group. Lancet 355 (2000), 1491–1498.
37. 37 Li, Z, Bishop, AC, Alyamani, M, et al. Conversion of abiraterone to D4A drives anti-tumour activity in prostate cancer. Nature 523 (2015), 347–351.
38. 38 Li, Z, Alyamani, M, Li, J, Redirecting abiraterone metabolism to biochemically fine-tune prostate cancer anti-androgen therapy. Nature 533 (2016), 547–551.
39. 39 Sweeney, CJ, Chen, YH, Carducci, M, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med 373 (2015), 737–746.
40. 40 James, ND, Sydes, MR, Clarke, NW, et al., for the STAMPEDE investigators. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet 387 (2016), 1163–1177.
41. 41 Panageas, KS, Ben-Porat, L, Dickler, MN, Chapman, PB, Schrag, D, When you look matters: the effect of assessment schedule on progression-free survival. J Natl Cancer Inst 99 (2007), 428–432.
42. 42 Gignac, GA, Morris, MJ, Heller, G, Schwartz, LH, Scher, HI, Assessing outcomes in prostate cancer clinical trials: a twenty-first century tower of Babel. Cancer 113 (2008), 966–974.